Across TCGA pan-cancer cohorts, LILRB4 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LILRB4 data layer compared with 30 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LILRB4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LILRB4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.
BLCA, LUAD, and SARC are the cancer types where LILRB4 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.